Lyra Therapeutics

Lyra Therapeutics, Inc. is a clinical-stage therapeutics company. It develops novel integrated drug and delivery solutions for the localized treatment of patients with ear, nose and throat, or ENT, diseases. The firms proprietary XTreo deliver medicines. The company was founded by Carmichael S. Roberts, George M. Whitesides, and Robert S. Langer in November 2005 and is headquartered in Watertown, MA.

Earnings data Q1 2021

Earnings data Q2 2021

Earnings data Q3 2021

Earnings data Q4 2021

Earnings data Q1 2022

Earnings data Q2 2022

Earnings data Q3 2022

Earnings data Q4 2022

Earnings data Q1 2023

Earnings data Q2 2023

Earnings data Q3 2023

Earnings data Q4 2023

Earnings data Q1 2024

Earnings data Q2 2024

Earnings data Q3 2024

Earnings data Q4 2024

Revenue

Cost of revenue

Gross profit

Operating expenses

SG&A

Other

Operating income

EBITDA

Net income

Earnings per share

Total assets

Current assets

Cash & equivalents

Receivables

Inventory

Non-current assets

Net PPE

Intangibles

Total liabilities

Current liabilities

Short term debt

Income tax payable

Non-current liabilities

Long-term debt

Total equity

Stockholders equity

Minority interest

Total liabilities & equity

Total debt

Net debt

Book value per share

Cash from operations

Funds from operations

Change in working capital

Cash from investing

Capital expenditure

Purchase/sale of investments

Purchase/sale of business

Other sources

Cash from financing

Change in stock

Change in debt

Cash dividends paid

Cash from other sources

Net change in cash

Free cash flow

WATERTOWN, Mass., Nov. 11, 2021 /PRNewswire/ -- Lyra Therapeutics, Inc. (Nasdaq: LYRA), a clinical-stage therapeutics company leveraging its proprietary XTreo™ platform to enable precise, sustained, and local delivery of medications to the ear, nose and throat (ENT) passages and other diseased tissues, today announced that Maria Palasis, Ph.D.

Lyra Therapeutics to Present at Upcoming Virtual Investor Conferences

Lyra Therapeutics, Inc. (LYRA) CEO Maria Palasis on Q3 2021 Results - Earnings Call Transcript

WATERTOWN, Mass., Nov. 9, 2021 /PRNewswire/ -- Lyra Therapeutics, Inc. (Nasdaq: LYRA), a clinical-stage therapeutics company leveraging its proprietary XTreo™ platform to enable precise, sustained, and local delivery of medications to the ear, nose and throat (ENT) passages and other diseased tissues, today reported financial results for the quarter ended September 30, 2021, and highlighted recent accomplishments.

Lyra Therapeutics Reports Third Quarter 2021 Financial Results and Provides Corporate Update

WATERTOWN, Mass., Nov. 2, 2021 /PRNewswire/ -- Lyra Therapeutics, Inc. (Nasdaq: LYRA), a clinical-stage therapeutics company leveraging its proprietary XTreo™ platform to enable precise, sustained, and local delivery of medications to the ear, nose and throat (ENT) passages and other diseased tissues will report third quarter 2021 financial results on Tuesday, November 9, 2021 after the close of market.

Lyra Therapeutics to Report Third Quarter 2021 Financial Results on November 9

WATERTOWN, Mass., Oct. 4, 2021 /PRNewswire/ -- Lyra Therapeutics, Inc. (Nasdaq: LYRA), a clinical-stage therapeutics company leveraging its proprietary XTreo™ platform to enable precise, sustained, and local delivery of medications to the ear, nose and throat (ENT) passages and other diseased tissues, announced that new, positive LYR-210 data from the LANTERN 6-month post-treatment evaluation and recently completed pharmacokinetic study, were the subject of two oral presentations at the 67th Annual Meeting of the American Rhinologic Society (ARS) on October 1-2.

Lyra Therapeutics Presents New Positive Phase 2 LANTERN 6-Month Follow-Up and LYR-210 Pharmacokinetic Data, and LANTERN Manuscript Wins Award at the 67th Annual Meeting of the American Rhinologic Society

LYR-210 is the First Drug-Eluting Product Candidate to Demonstrate Statistically Significant Symptom Improvement for Six Months with a Single Administration in Surgically Naïve Chronic Rhinosinusitis Patients

Lyra Therapeutics Announces Publication of Positive LANTERN Results in the International Forum of Allergy & Rhinology

LYR-210 Pharmacokinetic Study Chosen as a Top Clinical Abstract at ARS LYR-210 Pharmacokinetic Study Chosen as a Top Clinical Abstract at ARS

Lyra Therapeutics Announces Four Abstracts Selected for Presentations at Upcoming ERS and ARS Meetings, Including New LANTERN 6-Month Follow-Up and Pharmacokinetic Data

Seasoned investment banking executive brings extensive finance, partnering and M&A experience to the role Seasoned investment banking executive brings extensive finance, partnering and M&A experience to the role

Lyra Therapeutics Appoints Jason Cavalier as Chief Financial Officer

Results demonstrate XTreo™ technology platform provides targeted and sustained dosing of anti-inflammatory medication

Lyra Therapeutics Announces Publication of Preclinical Pharmacokinetics and Drug Release characterization for XTreo™ Technology Platform in the American Journal of Rhinology & Allergy

WATERTOWN, Mass., Sept. 07, 2021 (GLOBE NEWSWIRE) -- Lyra Therapeutics, Inc. (Nasdaq: LYRA), a clinical-stage therapeutics company leveraging its proprietary XTreo™ platform to enable precise, sustained, and local delivery of medications to the ear, nose and throat (ENT) passages and other diseased tissues, today announced that Maria Palasis, Ph.D., Lyra's President and Chief Executive Officer, will present in a virtual format at the H.C. Wainwright 23rd Annual Global Investment Conference. The presentation will be made available for on-demand viewing on Monday, September 13, 2021 at 7:00 a.m. ET.

Lyra Therapeutics to Present at the H.C. Wainwright 23rd Annual Global Investment Conference

WATERTOWN, Mass., Aug. 17, 2021 (GLOBE NEWSWIRE) -- Lyra Therapeutics, Inc. (Nasdaq: LYRA), a clinical-stage therapeutics company leveraging its proprietary XTreo™ platform to enable precise, sustained, and local delivery of medications to the ear, nose and throat (ENT) passages and other diseased tissues will host Chronic Rhinosinusitis (CRS) Key Opinion Leader Event on Tuesday, August 31, 2021 from 3:00 p.m. - 4:30 p.m. ET.

Lyra Therapeutics to Host Virtual Chronic Rhinosinusitis KOL Event on August 31

Lyra Therapeutics, Inc. (LYRA) CEO Maria Palasis on Q2 2021 Results - Earnings Call Transcript

WATERTOWN, Mass., July 26, 2021 (GLOBE NEWSWIRE) -- Lyra Therapeutics, Inc. (Nasdaq: LYRA), a clinical-stage therapeutics company leveraging its proprietary XTreo™ platform to enable precise, sustained, and local delivery of medications to the ear, nose and throat (ENT) passages and other diseased tissues, today announced the company will report second quarter 2021 financial results on Monday, August 9, 2021 after the close of market. Lyra will host a conference call and live webcast at 4:30 p.m. ET on the same day to discuss the results and provide a business update.

Lyra Therapeutics to Report Second Quarter 2021 Financial Results on August 9

WATERTOWN, Mass., July 12, 2021 (GLOBE NEWSWIRE) -- Lyra Therapeutics, Inc. (Nasdaq: LYRA), a clinical-stage therapeutics company leveraging its proprietary XTreo™ platform to enable precise, sustained, and local delivery of medications to the ear, nose and throat (ENT) passages and other diseased tissues, today announced that Maria Palasis, Ph.D., Lyra's President and Chief Executive Officer, will present at the William Blair Biotech Focus Conference on Thursday, July 15, 2021 at 10:00 a.m. ET. A live webcast of the fireside chat presentation will be available in the Investor Relations section of the Company's website at https://investors.lyratherapeutics.com. The webcast replay will be available for 30 days following the event.

Lyra Therapeutics to Present at Upcoming Virtual Healthcare Conference

-- Results Support 505(b)(2) NDA Pathway for LYR-210

Lyra Therapeutics Announces Positive Topline Results of Pharmacokinetic Study of LYR-210 in Patients with Chronic Rhinosinusitis

Lyra Therapeutics Inc (NASDAQ: LYRA) announced the successful outcome of an End-of-Phase 2 (EOP2) meeting with the FDA for LYR-210, its lead candidate for the treatment of chronic rhinosinusitis (CRS). Lyra and the FDA established key elements of the Phase 3 program.

Lyra Therapeutics Stock Is Trading Higher After Positive FDA Meeting Outcome For Rhinosinusitis Program

WATERTOWN, Mass.--(BUSINESS WIRE)--Lyra Therapeutics, Inc. (Nasdaq: LYRA), a clinical-stage therapeutics company leveraging its proprietary XTreo™ platform to enable precise, sustained, and local delivery of medications to the ear, nose and throat (ENT) passages and other diseased tissues, today announced the successful outcome of an End-of-Phase 2 (EOP2) meeting with the U.S. Food and Drug Administration (FDA) for LYR-210, its lead candidate for the treatment of chronic rhinosinusitis (CRS). L

Lyra Therapeutics Announces Positive Outcome of End-of-Phase 2 Meeting with the FDA for LYR-210 for the Treatment of Chronic Rhinosinusitis

WATERTOWN, Mass.--(BUSINESS WIRE)--Lyra Therapeutics, Inc. (Nasdaq: LYRA), a clinical-stage therapeutics company focused on the development and commercialization of novel integrated drug and delivery solutions for the localized treatment of patients with ear, nose and throat (ENT) diseases, today announced that Maria Palasis, Ph.D., Lyra's President and Chief Executive Officer, will participate in a fireside chat at the William Blair 41st Annual Growth Stock Conference on Thursday, June 3, 2021

Lyra Therapeutics to Present at the William Blair 41st Annual Growth Stock Conference

WATERTOWN, Mass.--(BUSINESS WIRE)--Lyra Therapeutics To Present At The Jefferies Virtual Healthcare Conference

Lyra Therapeutics To Present At The Jefferies Virtual Healthcare Conference

Lyra Therapeutics, Inc. (LYRA) CEO Maria Palasis on Q1 2021 Results - Earnings Call Transcript

WATERTOWN, Mass.--(BUSINESS WIRE)--Lyra Therapeutics Reports First Quarter 2021 Financial Results and Provides Corporate Update

Lyra Therapeutics Reports First Quarter 2021 Financial Results and Provides Corporate Update

WATERTOWN, Mass.--(BUSINESS WIRE)--Lyra Therapeutics to Present at the BofA Securities 2021 Virtual Health Care Conference

Lyra Therapeutics to Present at the BofA Securities 2021 Virtual Health Care Conference

WATERTOWN, Mass.--(BUSINESS WIRE)--Lyra Therapeutics to Report First Quarter 2021 Financial Results and Provide Corporate Update

Lyra Therapeutics to Report First Quarter 2021 Financial Results and Provide Corporate Update

WATERTOWN, Mass.--(BUSINESS WIRE)--Lyra Therapeutics Presents Positive Full Data Set from LANTERN Phase 2 Study of LYR-210 at COSM 2021 Virtual

Lyra Therapeutics Presents Positive Full Data Set from LANTERN Phase 2 Study of LYR-210 at COSM 2021 Virtual

WATERTOWN, Mass.--(BUSINESS WIRE)--Lyra Therapeutics to Present LANTERN Phase 2 Study Results for LYR 210 in Oral Presentation at COSM 2021 Virtual

News for Lyra Therapeutics Stock (LYRA)